{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:33Z","timestamp":1793142753163,"version":"4.5.0"},"reference-count":65,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic lymphocytic leukemia (CLL)\u2013related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to geriatric characteristics and aim for an improvement in health-related quality of life (HRQoL) as a primary treatment goal. In the HOVON139\/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67). However, prolonged venetoclax exposure as consolidation treatment led to increased toxicity with limited effect on minimal residual disease. To assess the impact of geriatric assessment on treatment outcomes and the patients\u2019 HRQoL, patient-reported outcomes (PROs), including function, depression, cognition, nutrition, physical performance, muscle parameters, comorbidities, and the European Organization for Research and Treatment of Cancer C30 and CLL17 questionnaires were assessed. At baseline, geriatric impairments were present in &amp;gt;90% of patients and \u22652 impairments present in 60% of patients predicted grade \u22653 nonhematological toxicity. During treatment, the number of geriatric impairments diminished significantly and clinically relevant improvements in HRQoL subscales were reached for global health status, physical functioning, role functioning, emotional functioning, fatigue, dyspnea, physical condition or fatigue, and worries or fears related to health and functioning. These improvements were comparable for patients receiving venetoclax consolidation and patients in whom treatment could mostly be discontinued. Collectively, frontline fixed-duration Ven-O improves overall PROs in older, unfit patients with CLL with and without geriatric impairments. This study was registered at EudraCT as 2015-004985-27 and the Netherlands Trial Register as NTR6043.<\/jats:p>","DOI":"10.1182\/blood.2023020195","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:43:54Z","timestamp":1687797834000},"page":"1131-1142","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-1203","authenticated-orcid":false,"given":"Lina","family":"van der Straten","sequence":"first","affiliation":[{"name":"1Department of Immunology, Erasmus MC, Rotterdam, The Netherlands"},{"name":"2Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"},{"name":"3Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-0609","authenticated-orcid":false,"given":"Claudia A. M.","family":"Stege","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam\u2013Treatment and Quality of Life, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Kersting","sequence":"additional","affiliation":[{"name":"5Department of Hematology, HAGA Teaching Hospital, The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[{"name":"6Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dubois","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A.","family":"Dobber","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens H. M.","family":"Mellink","sequence":"additional","affiliation":[{"name":"9Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-6198","authenticated-orcid":false,"given":"Anne-Marie F.","family":"van der Kevie-Kersemaekers","sequence":"additional","affiliation":[{"name":"9Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo M.","family":"Evers","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8285-7870","authenticated-orcid":false,"given":"Fransien","family":"de Boer","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"Koene","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7588-0991","authenticated-orcid":false,"given":"John","family":"Schreurs","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van der Klift","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjo A.","family":"Velders","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine, Gelderland Valley Hospital, Ede, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"van der Spek","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke M.","family":"van der Straaten","sequence":"additional","affiliation":[{"name":"16Department of Internal Medicine, St Jansdal Hospital, Harderwijk, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mels","family":"Hoogendoorn","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"van Gelder","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardus F. M.","family":"Posthuma","sequence":"additional","affiliation":[{"name":"19Department of Internal Medicine, Reinier The Graaf Hospital, Delft, The Netherlands"},{"name":"20Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein P. J.","family":"Visser","sequence":"additional","affiliation":[{"name":"21Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Houtenbos","sequence":"additional","affiliation":[{"name":"22Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile A. M.","family":"Idink","sequence":"additional","affiliation":[{"name":"23Department of Internal Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila E.","family":"Issa","sequence":"additional","affiliation":[{"name":"24Department of Internal Medicine, Jeroen Bosch Hospital, s-Hertogenbosch, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen C.","family":"Dompeling","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Isala Hospital, Zwolle, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk C. T.","family":"van Zaanen","sequence":"additional","affiliation":[{"name":"26Department of Internal Medicine, St Franciscus Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Hendrik","family":"Veelken","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Levenga","sequence":"additional","affiliation":[{"name":"27Department of Internal Medicine, Groene Hart Hospital, Gouda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine W.","family":"Tick","sequence":"additional","affiliation":[{"name":"28Department of Internal Medicine, Maxima Medical Center, Eindhoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim E.","family":"Terpstra","sequence":"additional","affiliation":[{"name":"29Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne H.","family":"Tonino","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-3220","authenticated-orcid":false,"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Erasmus MC, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"2Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2023092815303178300_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjh.16397","article-title":"Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016","volume":"189","author":"van der Straten","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"2023092815303178300_bib2","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1038\/bcj.2016.105","article-title":"Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients","volume":"6","author":"da Cunha-Bang","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023092815303178300_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.13720","article-title":"Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: a population-based study","volume":"108","author":"Steingr\u00edmsson","year":"2022","journal-title":"Eur J Haematol"},{"issue":"9","key":"2023092815303178300_bib4","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","article-title":"Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973\u20132003 in Sweden","volume":"94","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2023092815303178300_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2018.1508674","article-title":"A\u00a0simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients","volume":"60","author":"Molica","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2023092815303178300_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023092815303178300_bib7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: a systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"2023092815303178300_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an International Society of Geriatric Oncology (SIOG) Task Force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"issue":"26","key":"2023092815303178300_bib9","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023092815303178300_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"25","key":"2023092815303178300_bib11","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023092815303178300_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023092815303178300_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"25","key":"2023092815303178300_bib14","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A\u00a0phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"O'Brien","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2023092815303178300_bib15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10232","key":"2023092815303178300_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"2023092815303178300_bib17","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2023092815303178300_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"34","key":"2023092815303178300_bib19","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023092815303178300_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"2023092815303178300_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"9","key":"2023092815303178300_bib22","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"issue":"10277","key":"2023092815303178300_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"2023092815303178300_bib24","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023092815303178300_bib25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2023092815303178300_bib26","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"2023092815303178300_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-022-00669-7","article-title":"Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989\u20132018","volume":"12","author":"van der Straten","year":"2022","journal-title":"Blood Cancer J"},{"issue":"25","key":"2023092815303178300_bib28","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2023092815303178300_bib29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"12","key":"2023092815303178300_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1532-5415.1983.tb03391.x","article-title":"Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living","volume":"31","author":"Katz","year":"1983","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"2023092815303178300_bib31","first-page":"609","article-title":"Scales to measure competence in everyday activities","volume":"24","author":"Lawton","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"2023092815303178300_bib32","first-page":"165","volume-title":"Clinical Gerontology: A Guide to Assessment and Intervention","author":"Shelk","year":"1986"},{"issue":"6","key":"2023092815303178300_bib33","doi-asserted-by":"crossref","first-page":"M366","DOI":"10.1093\/gerona\/56.6.M366","article-title":"Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF)","volume":"56","author":"Rubenstein","year":"2001","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"2023092815303178300_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J\u00a0Psychiatr Res"},{"issue":"1","key":"2023092815303178300_bib35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"4","key":"2023092815303178300_bib36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"issue":"5","key":"2023092815303178300_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"2023092815303178300_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","article-title":"International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high-and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia","volume":"27","author":"van de Poll-Franse","year":"2018","journal-title":"Qual Life Res"},{"key":"2023092815303178300_bib39","author":"Fayers","year":"1995"},{"issue":"9","key":"2023092815303178300_bib40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","article-title":"Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life","volume":"52","author":"Wyrwich","year":"1999","journal-title":"J\u00a0Clin Epidemiol"},{"key":"2023092815303178300_bib41","author":"Cohen","year":"2013"},{"issue":"2","key":"2023092815303178300_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/erp.11.9","article-title":"A\u00a0point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"2023092815303178300_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023092815303178300_bib44","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"6","key":"2023092815303178300_bib45","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","volume":"105","author":"Nielsen","year":"2020","journal-title":"Haematologica"},{"key":"2023092815303178300_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/9781119468868.ch31","volume-title":"The American Cancer Society's Principles of Oncology: Prevention to Survivorship","author":"Stein","year":"2018"},{"issue":"7","key":"2023092815303178300_bib47","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ijc.31957","article-title":"Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials","volume":"144","author":"Hwang","year":"2019","journal-title":"Int J Cancer"},{"issue":"9","key":"2023092815303178300_bib48","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/annonc\/mdv181","article-title":"Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors","volume":"26","author":"Howell","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"2023092815303178300_bib49","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","article-title":"Patient-reported outcomes in cancer care\u2014hearing the patient voice at greater volume","volume":"14","author":"LeBlanc","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"2023092815303178300_bib50","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"2023092815303178300_bib51","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A\u00a0comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"2023092815303178300_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jgo.2013.02.002","article-title":"Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer","volume":"4","author":"Wildes","year":"2013","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"13","key":"2023092815303178300_bib53","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023092815303178300_bib54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2023092815303178300_bib55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00277-014-2161-6","article-title":"Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL\/SLL in the Netherlands","volume":"94","author":"van den Broek","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"2023092815303178300_bib56","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s11136-015-1039-y","article-title":"Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study","volume":"24","author":"Holtzer-Goor","year":"2015","journal-title":"Qual Life Res"},{"issue":"3","key":"2023092815303178300_bib57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2023092815303178300_bib58","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/ejh.13503","article-title":"Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire","volume":"105","author":"Youron","year":"2020","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2023092815303178300_bib59","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1182\/blood-2018-99-117127","article-title":"Venetoclax improves quality of life for patients with elapsed\/refractory chronic lymphocytic leukemia [abstract]","volume":"132","author":"Cochrane","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023092815303178300_bib60","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/HS9.0000000000000336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 Trial of the GCLLSG)","volume":"4","author":"Kutsch","year":"2020","journal-title":"Hemasphere"},{"issue":"10","key":"2023092815303178300_bib61","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.3324\/haematol.2019.238808","article-title":"Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial","volume":"105","author":"Ghia","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"2023092815303178300_bib62","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.2006.05.6929","article-title":"Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group","volume":"25","author":"Eichhorst","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023092815303178300_bib63","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3109\/10428194.2011.649479","article-title":"Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial","volume":"53","author":"Else","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2023092815303178300_bib64","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/ajh.26260","article-title":"Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: results from the randomized, phase 3 CLL14 trial","volume":"96","author":"Al-Sawaf","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2023092815303178300_bib65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcbs.2017.02.005","article-title":"Unmet psychosocial supportive care needs and psychological distress in haematological cancer survivors: the moderating role of psychological flexibility","volume":"6","author":"Swash","year":"2017","journal-title":"J\u00a0Context Behav Sci"}],"updated-by":[{"DOI":"10.1182\/blood.2024025363","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/13\/1131\/2081936\/blood_bld-2023-020195-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/13\/1131\/2081936\/blood_bld-2023-020195-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:31:38Z","timestamp":1695915098000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/13\/1131\/496538\/Fixed-duration-venetoclax-plus-obinutuzumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":65,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020195","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2024025363","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}